JP2019524834A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524834A5
JP2019524834A5 JP2019508879A JP2019508879A JP2019524834A5 JP 2019524834 A5 JP2019524834 A5 JP 2019524834A5 JP 2019508879 A JP2019508879 A JP 2019508879A JP 2019508879 A JP2019508879 A JP 2019508879A JP 2019524834 A5 JP2019524834 A5 JP 2019524834A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
epilepsy
agent according
patient
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524834A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/047505 external-priority patent/WO2018035408A1/en
Publication of JP2019524834A publication Critical patent/JP2019524834A/ja
Publication of JP2019524834A5 publication Critical patent/JP2019524834A5/ja
Pending legal-status Critical Current

Links

JP2019508879A 2016-08-18 2017-08-18 ビグアナイド系による発達障害の治療方法 Pending JP2019524834A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376488P 2016-08-18 2016-08-18
US62/376,488 2016-08-18
PCT/US2017/047505 WO2018035408A1 (en) 2016-08-18 2017-08-18 Methods of treating developmental disorders with biguanides

Publications (2)

Publication Number Publication Date
JP2019524834A JP2019524834A (ja) 2019-09-05
JP2019524834A5 true JP2019524834A5 (enExample) 2020-09-24

Family

ID=61190982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508879A Pending JP2019524834A (ja) 2016-08-18 2017-08-18 ビグアナイド系による発達障害の治療方法

Country Status (9)

Country Link
US (2) US10123979B2 (enExample)
EP (1) EP3484452A4 (enExample)
JP (1) JP2019524834A (enExample)
KR (1) KR20190039974A (enExample)
CN (1) CN109715144A (enExample)
AU (1) AU2017313823A1 (enExample)
CA (1) CA3033967A1 (enExample)
MX (1) MX2019001937A (enExample)
WO (1) WO2018035408A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970884A4 (en) 2013-03-14 2016-11-02 Univ Florida DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS
WO2016196324A1 (en) 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides
JP7526455B2 (ja) 2017-04-17 2024-08-01 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
JP7620988B2 (ja) 2019-09-20 2025-01-24 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出
GB202008699D0 (en) * 2020-06-09 2020-07-22 Healx Ltd Treatment
CN113318111A (zh) * 2021-06-21 2021-08-31 浙江大学 Nav1.1激动剂在制备治疗自闭症的药物中的应用
EP4440560A1 (en) * 2021-12-01 2024-10-09 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US8252321B2 (en) * 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
CN102058888B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种治疗能量代谢异常的药物组合物和其应用
WO2012081713A1 (ja) * 2010-12-13 2012-06-21 学校法人福岡大学 血液脳関門障害症候群治療薬
KR20160037169A (ko) * 2013-06-26 2016-04-05 레트 신드롬 리서치 트러스트 레트 증후군 및 그를 위한 치료
WO2018035408A1 (en) 2016-08-18 2018-02-22 Ovid Therapeutics Inc. Methods of treating developmental disorders with biguanides

Similar Documents

Publication Publication Date Title
JP2019524834A5 (enExample)
US10912754B2 (en) Methods and compositions for treating excessive sleepiness
AU2018201060B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
US9718766B2 (en) High penetration drugs and their compositions thereof for treatment of parkinson diseases
US20200179336A1 (en) Methods of treating neurological and psychiatric disorders
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP2004519469A5 (enExample)
JP2010518122A5 (enExample)
JP2011510014A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
RU2012133528A (ru) Способ лечения аутоиммунного демиелинизирующего заболевания центральной нервной системы (варианты)
BRPI0605026A (pt) composição farmacêutica estável de glimepirida com liberação imediata e metformina com liberação prolongada
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
JP2014508758A5 (enExample)
RU2013137645A (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
JP2018531273A5 (enExample)
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
TW201828932A (zh) 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
CN111821299A (zh) 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用
JPWO2019232130A5 (enExample)
ES2366570T3 (es) Asociación de un inhibidor de la corriente if sinusal y de un inhibidor de la enzima de conversión de la angiotensina.
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
US11850220B2 (en) Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
JP2024041865A (ja) パ－キンソン病治療用の新規高透過薬物及びその組成物